GLP-1 receptor agonist-associated tumor adverse events: a real-world study from 2004 to 2021 based on FAERS
Tesamorelin works through growth hormone pathways to target visceral fat specifically, while retatrutide activates GLP-1, GIP, and glucagon receptors to reduce overall body weight and liver fat
A common description is that it feels like having a heavy meal sitting in the stomach, which reduces cravings for calorie-dense foods
The introduction of new obesity treatments in the coming years will significantly improve the lives of people affected by obesity.
This can lead to potentially not getting enough nutrients like zinc, protein, iron, or calories, which can also trigger hair change
Interim data from REDEFINE 1 have suggested meaningful body weight reductions in adults with obesity over 68 weeks, comparing favourably with semaglutide alone